ERBB2 and breast cancer: Phase II (NCT02983071) trial of lerocliclib (G1T38, 5, Figure 3) examined the effect in combination with fulvestrant in hormone receptor-positive, HER2-negative locally advanced metastatic BC while another phase II study combined lerociclib with osimertinib in EGFR-mutant non-small cell lung cancer (NCT03455829) [54,55].